Xoma's Anti-IL1-beta tests the inflammation model of diabetes

Availability: In stock.

$0.00

Product Description

Recent research has noted the importance of inflammation in diabetes, with a central role for IL-1 beta. Thus therapies that target IL-1-beta could represent a promising new treatment strategy. This report reviews the evidence and rationale for use of anti-IL1 therapies in both type 1 and type 2 diabetes.

XOMA's anti-IL1 beta antibody is in phase II trials and data are expected by year-end. Several other IL-1 inhibitors are also in clinical studies for type 2 and/or type 1 diabetes, including Regeneron's rilonacept, Novartis' canakinumab and Biovitrum's anakinra. While there is good rationale for testing these drugs in diabetes, there are lingering questions about safety and efficacy, which are reviewed herein. In addition, the market opportunity for these drugs may not be as good as it first appears. Data are limited in type 1 diabetes and competition is intense in type 2 diabetes.

Published: April 6th, 2010

Number of pages: 21

Authors: Dr. Drew Applefield and Dr. Ilana Fogelman

License *

Single User (Allows distribution to two others within User's place of employment) +$2,500.00
Multiuser (Allows unlimited distribution within User's place of employment) +$5,000.00

* Required Fields

$0.00

Add Items to Cart

Category Navigation:

You're currently on:

Xoma's Anti-IL1-beta tests the inflammation model of diabetes

Product Description

Recently Viewed Products

My Cart

Compare Products